Connect with us

Health Broadcasting Service

Gilead quarterly profit falls as COVID antiviral sales decrease

HBS Reporting

Gilead quarterly profit falls as COVID antiviral sales decrease

Gilead quarterly profit falls as COVID antiviral sales decrease

Aug 2 (Reuters) – Gilead Sciences Inc (GILD.O) on Tuesday said its second-quarter adjusted profit fell due to higher research and royalty costs as well as a downturn in sales of its COVID-19 antiviral drug Veklury.Quarterly revenue, however, rose 1% to $6.3 billion, which was ahead of the average Wall Street estimate of $5.85 billion, according to Refinitiv data.The biotech company said adjusted quarterly profit fell 13% to $1.58 per share, which also topped the average analyst estimate of $1.52. Net income fell to 91 cents per share from $1.21 per share.Sales of COVID-19 treatment remdesivir, which is sold under the brand name Veklury, fell 46% to $445 million, but still came in ahead of analysts’ estimates of $390 million.”Sales declined as hospitalization rates declined in most geographies,” Gilead Chief Commercial Officer Johanna Mercier said on a conference call, adding the company remains ready to supply Veklury if needed.Cancer drug Trodelvy – shown in a recent trial to modestly delay tumor growth in women with the most common form of breast cancer – saw sales rise 79% to $159 million. Sales of Gilead’s cancer cell therapies rose by a robust 68% to $368 million.HIV drug sales, driven by demand for higher-priced products, rose 7% to $4.2 billion.Gilead announced that the U.S. Food and Drug Administration will decide by Dec. 27 whether to approve its long-acting HIV medication lenacapavir.”We’ve seen somewhat of a recovery in core products from last quarter’s weaker results,” BMO Capital Markets analyst Evan Seigerman said in a research note. He pointed to particular strength in HIV and cell therapy products.For full-year 2022, California-based Gilead sightly raised its forecast for adjusted earnings per share to between $6.35 to $6.75 from a previous view of $6.20 to $6.70. Gilead said it now expects product sales of $24.5 billion to $25 billion, up from a prior estimate of $23.8 billion to $24.3 billion.Gilead were up 1% at $60.15 in after hours trading.

Continue Reading
You may also like...
Click to comment

Leave a Reply

Your email address will not be published.

More in HBS Reporting